Ankyra Therapeutics targets a bigger immunotherapy problem with anchored monoclonal antibodies
Cancer antibodies can be powerful but toxic. Ankyra’s anchored platform asks whether local retention can widen immunotherapy’s safety window.
Pharma & Biotech
Pharma & Biotech
Takara Bio USA unveils AACR benchmark data for Trekker FX, but will cancer labs switch?
Takara Bio USA says Trekker FX outperformed conventional spatial methods in a cancer benchmark study. Read what this could mean for oncology research.
Pharma & Biotech
Why CytoDyn Inc.’s leronlimab data could reshape TNBC immunotherapy strategies
Discover how CytoDyn Inc.’s leronlimab data could reshape TNBC immunotherapy and expand checkpoint treatment potential.
Pharma & Biotech
Avacta’s pre|CISION exatecan conjugate reaches Phase 1 as competition in targeted topo I inhibitors intensifies
Avacta opens Phase 1 trial of FAP-Exd (AVA6103) in four advanced solid tumors. Analysis of what the sustained-release exatecan conjugate must prove in 2026.
Pharma & Biotech
What the Senhwa Biosciences and CellType collaboration reveals about AI’s role in oncology pipelines
Senhwa Biosciences and CellType partner to advance silmitasertib with AI. Discover how the collaboration could reshape immunotherapy research.
Pharma & Biotech
Taiwan biotech Great Novel Therapeutics launches Phase I trial for GNTbm-38 cancer therapy
Great Novel Therapeutics launches Phase I trial of GNTbm-38 after FDA IND approval. Discover what this epigenetic cancer immunotherapy could change.
Pharma & Biotech
Avacta (AIM: AVCT) FAP-Exd data challenges Enhertu on tumor selectivity ahead of Phase 1 start
Avacta Therapeutics (AIM: AVCT) has published preclinical data showing that its FAP-targeted payload delivery platform, FAP-Exd (AVA6103), outperforms the marketed antibody drug conjugate trastuzumab deruxtecan across three pharmacokinetic measures, with a Phase 1 clinical trial expected to begin in the first quarter of 2026. What the AI-generated comparator actually enables The methodological choice here deserves